Published in J Immunol Methods on July 01, 2003
A panel of neuron-enriched proteins as markers for traumatic brain injury in humans. J Neurotrauma (2009) 1.39
Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One (2013) 1.32
Biomarker evidence for mild central nervous system injury after surgically-induced circulation arrest. Brain Res (2008) 1.15
Axonal damage and outcome in subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry (2006) 1.08
Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J Neurol Neurosurg Psychiatry (2005) 1.07
Phosphorylation and compactness of neurofilaments in multiple sclerosis: indicators of axonal pathology. Exp Neurol (2008) 0.98
CSF neurofilament proteins in the differential diagnosis of dementia. J Neurol Neurosurg Psychiatry (2007) 0.97
CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol (2009) 0.96
Review on intermediate filaments of the nervous system and their pathological alterations. Histochem Cell Biol (2013) 0.92
In vivo monitoring of neuronal loss in traumatic brain injury: a microdialysis study. Brain (2011) 0.91
Cerebrospinal fluid biomarkers in Guillain-Barré syndrome--where do we stand? J Neurol (2009) 0.90
Serial soluble neurofilament heavy chain in plasma as a marker of brain injury after cardiac arrest. Crit Care (2012) 0.87
Soluble beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosis. PLoS One (2011) 0.86
Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALS. PLoS One (2012) 0.86
The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis. PLoS One (2011) 0.85
The diagnostic and prognostic value of neurofilament heavy chain levels in immune-mediated optic neuropathies. Mult Scler Int (2012) 0.84
Death receptor 6 (DR6) antagonist antibody is neuroprotective in the mouse SOD1G93A model of amyotrophic lateral sclerosis. Cell Death Dis (2013) 0.84
Axonal damage in the making: neurofilament phosphorylation, proton mobility and magnetisation transfer in multiple sclerosis normal appearing white matter. Exp Neurol (2011) 0.83
Neurofilament proteins as body fluid biomarkers of neurodegeneration in multiple sclerosis. Mult Scler Int (2011) 0.83
Effects of repeated intrathecal triamcinolone-acetonide application on cerebrospinal fluid biomarkers of axonal damage and glial activity in multiple sclerosis patients. Mol Diagn Ther (2014) 0.82
ALS biomarkers for therapy development: State of the field and future directions. Muscle Nerve (2015) 0.81
Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.80
Elevated levels of S100B, tau and pNFH in cerebrospinal fluid are correlated with subtypes of Guillain-Barré syndrome. Neurol Sci (2012) 0.79
Blood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation. Mult Scler Int (2011) 0.78
A novel biomarker for retinal degeneration: vitreous body neurofilament proteins. J Neural Transm (Vienna) (2009) 0.77
Neurofilaments as a plasma biomarker for ICU-acquired weakness: an observational pilot study. Crit Care (2014) 0.77
Neurofilament light chain level is a weak risk factor for the development of MS. Neurology (2016) 0.77
Progression in multiple sclerosis is associated with low endogenous NCAM. J Neurochem (2013) 0.76
Cerebrospinal Fluid Levels of Phosphorylated Neurofilament Heavy as a Diagnostic Marker of Canine Degenerative Myelopathy. J Vet Intern Med (2017) 0.75
Investigation of sex-specific effects of apolipoprotein E on severity of EAE and MS. J Neuroinflammation (2015) 0.75
Neurofilaments in CSF As Diagnostic Biomarkers in Motor Neuron Disease: A Meta-Analysis. Front Aging Neurosci (2016) 0.75
Central nervous system sarcoidosis--diagnosis and management. QJM (1999) 3.11
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain (2000) 2.84
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology (2009) 2.58
Streptococcal infection, Tourette syndrome, and OCD: is there a connection? Neurology (2009) 2.33
The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review. J Neurol Neurosurg Psychiatry (2010) 2.29
Frontotemporal dementia in elderly individuals. Arch Neurol (2012) 2.21
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology (2009) 2.10
Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry (2002) 2.08
Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. Eur J Neurol (2006) 2.04
Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry (1996) 2.02
Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology (2009) 1.93
Underenumeration in the 1991 census. BMJ (1993) 1.71
Elevated serum levels of tumor necrosis factor-alpha in Guillain-Barré syndrome. Ann Neurol (1993) 1.71
Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology (2011) 1.70
Anti-basal ganglia antibodies: a possible diagnostic utility in idiopathic movement disorders? Arch Dis Child (2004) 1.67
Adaptation of the nitrate reductase and Griess reaction methods for the measurement of serum nitrate plus nitrite levels. Ann Clin Biochem (1997) 1.63
Fatigue is not associated with raised inflammatory markers in multiple sclerosis. Neurology (2001) 1.58
Hypertrophic obstructive cardiomyopathy in a neonate with the carbohydrate-deficient glycoprotein syndrome. J Inherit Metab Dis (1992) 1.58
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology (2007) 1.56
Tourette's syndrome: a cross sectional study to examine the PANDAS hypothesis. J Neurol Neurosurg Psychiatry (2003) 1.51
Isoelectric focusing versus quantitative measurements in the detection of intrathecal local synthesis of IgG. Clin Chim Acta (1990) 1.45
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology (2007) 1.45
Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice. Mult Scler (2011) 1.43
Oligoclonal immunoglobulins and plasma cells in spinal fluid of patients with multiple sclerosis. Br Med J (1979) 1.41
Inactivation of metronidazole by aerobic organisms. J Antimicrob Chemother (1979) 1.41
Lack of serum oligoclonal antibody responses to Chlamydophila pneumoniae in multiple sclerosis. Eur Neurol (2005) 1.38
Anti-basal ganglia antibodies in acute and persistent Sydenham's chorea. Neurology (2002) 1.38
The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain (2001) 1.32
A quantitative technique for growing human adult skeletal muscle in culture starting from mononucleated cells. J Neurol Sci (1977) 1.32
Late recurrences of Sydenham's chorea are not associated with anti-basal ganglia antibodies. J Neurol Neurosurg Psychiatry (2004) 1.32
The evidence for a role of B cells in multiple sclerosis. Neurology (2012) 1.32
Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry (2001) 1.30
Seven years' experience with antilymphoblast globulin for renal transplantation from cadaver donors. Ann Surg (1976) 1.26
Markers for gene expression in cultured cells from the nervous system. J Biol Chem (1972) 1.26
Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology (2012) 1.25
Blood-brain barrier damage in patients with bacterial meningitis: association with tumor necrosis factor-alpha but not interleukin-1 beta. J Infect Dis (1992) 1.20
The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis. Ann Neurol (1991) 1.20
A rapid method for detecting oligoclonal IgG in unconcentrated CSF, by agarose isoelectric focusing, transfer to cellulose nitrate and immunoperoxidase staining. J Neuroimmunol (1983) 1.19
Diagnostic strategy used to establish etiologies of encephalitis in a prospective cohort of patients in England. J Clin Microbiol (2011) 1.17
Defective galactosylation of serum transferrin in galactosemia. Glycobiology (1998) 1.17
Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lett (1999) 1.17
Herpes simplex encephalitis: an audit of the use of laboratory diagnostic tests. QJM (2004) 1.15
Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain (2002) 1.13
Genetic and environmental factors and the distribution of multiple sclerosis in Europe. Eur J Neurol (2010) 1.13
Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler (2005) 1.11
Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. Brain (2008) 1.10
Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: final report. Lancet (1982) 1.09
Axonal damage and outcome in subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry (2006) 1.08
Isoelectric focusing of cerebrospinal fluid immunoglobulin G: an annotated update. Ann Clin Biochem (1990) 1.08
Cerebrospinal fluid ferritin in brain necrosis: evidence for local synthesis. Clin Chim Acta (1993) 1.07
Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis. Brain (1997) 1.07
New ultramicromethod for concentration of cerebrospinal fluid. Lancet (1976) 1.07
An ELISA for glial fibrillary acidic protein. J Immunol Methods (2004) 1.07
Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J Neurol Neurosurg Psychiatry (2005) 1.07
Poststreptococcal acute disseminated encephalomyelitis with basal ganglia involvement and auto-reactive antibasal ganglia antibodies. Ann Neurol (2001) 1.06
Laboratory diagnosis of multiple sclerosis: immunological and biochemical aspects. Br Med Bull (1977) 1.06
Double-blind, controlled trial of immunosuppression in treatment of multiple sclerosis. Lancet (1980) 1.06
Is it multiple sclerosis or not? Neurology (2001) 1.06
Antigen-dependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigen-specific B cells. J Immunol (1998) 1.05
Relationship of UV exposure to prevalence of multiple sclerosis in England. Neurology (2011) 1.05
Oral contraceptive induced chorea: another condition associated with anti-basal ganglia antibodies. J Neurol Neurosurg Psychiatry (2004) 1.05
Olivopontocerebellar atrophy of neonatal onset and disialotransferrin developmental deficiency syndrome. Arch Dis Child (1991) 1.04
Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behçet's disease involving the nervous system. J Neurol Neurosurg Psychiatry (1995) 1.04
Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Neurology (1999) 1.04
Evidence for increased nitric oxide production in multiple sclerosis. J Neurol Neurosurg Psychiatry (1995) 1.03
Genotypes and phenotypes of patients in the UK with carbohydrate-deficient glycoprotein syndrome type 1. J Inherit Metab Dis (2000) 1.03
CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology (2004) 1.03
Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry (2002) 1.02
A study of oligoclonal band negative multiple sclerosis. J Neurol Neurosurg Psychiatry (1996) 1.02
Free light chains in the cerebrospinal fluid: an indicator of recent immunological stimulation. J Neurol Neurosurg Psychiatry (1985) 1.02
In vivo relationship of tumor necrosis factor-alpha to blood-brain barrier damage in patients with active multiple sclerosis. J Neuroimmunol (1992) 1.02
Cerebrospinal fluid tau concentrations in HIV infected patients with suspected neurological disease. Sex Transm Infect (2000) 1.01
Antibody synthesis within the central nervous system: comparisons of CSF IgG indices and electrophoresis. J Clin Pathol (1983) 1.00
A specific and sensitive ELISA for measuring S-100b in cerebrospinal fluid. J Immunol Methods (1997) 0.99
Post-streptococcal opsoclonus-myoclonus syndrome associated with anti-neuroleukin antibodies. J Neurol Neurosurg Psychiatry (2006) 0.99
Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease. Neurosci Lett (2003) 0.99